Activyl Tick Plus

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

indoxacarb, permethrin

Available from:

Intervet International BV

ATC code:

QP53AC54

INN (International Name):

indoxacarb, permethrin

Therapeutic group:

Klieb

Therapeutic area:

permethrin, kombinazzjonijiet, Ektoparasitaċidali għall-użu topiku, inklużi. insettiċidi

Therapeutic indications:

Trattament ta 'infestazzjonijiet tal-briegħed (Ctenocephalides felis); il-prodott għandu effikaċja insettiċida persistenti sa 4 ġimgħat kontra Ctenocephalides felis. Il-prodott għandu effikaċja acaricidal persistenti sa 5 ġimgħat kontra Ixodes ricinus u sa 3 ġimgħat kontra Rhipicephalus sanguineus. Trattament wieħed jipprovdi attività ta 'kontra r-riħ (Phlebotomus perniciosus) kontra r-riħ (kontra t-tmigħ) sa 3 ġimgħat.

Product summary:

Revision: 9

Authorization status:

Irtirat

Authorization date:

2012-01-09

Patient Information leaflet

                                19
B. FULJETT TA' TAGĦRIF FIL-PAKKETT
Prodott mediċinali li m’għadux awtorizzat
20
FULJETT TA’ TAGĦRIF FIL-PAKKETT:
ACTIVYL TICK PLUS SOLUZZJONI _SPOT-ON_ GĦAL KLIEB
1.
L-ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-KUMMERĊ, U L-
ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-MANIFATTURA
RESPONSABBLI LI JĦALLI L-KONSENJA TMUR FIS-SUQ , JEKK DIFFERENTI
Sid l-Awtorizzazzjoni tal-Kummerċ:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
In-Netherlands
Manifattur responsabbli li jħalli l-konsenja tmur fis-suq:
Intervet Productions SA
Rue de Lyons
27460 Igoville
Franza
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Activyl Tick Plus soluzzjoni
_spot-on_
għal klieb żgħar ħafna
Activyl Tick Plus soluzzjoni
_spot-on_
għal-klieb żgħar
Activyl Tick Plus soluzzjoni
_spot-on_
għal-klieb medji
Activyl Tick Plus soluzzjoni
_spot-on_
għal-klieb kbar
Activyl Tick Plus soluzzjoni
_spot-on_
għal-klieb kbar ħafna
Indoxacarb, permethrin
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
SUSTANZA ATTIVA:
ml wieħed fih 150 mg indoxacarb u 480 mg permethrin.
Pipetta waħda tagħti:
VOLUM
(ML)
INDOXACARB
(MG)
PERMETHRIN
(MG)
Activyl
Tick Plus soluzzjoni
_spot-on_
għal klieb żgħar ħafna
0.5
75
240
Activyl
Tick Plus soluzzjoni
_spot-on_
għal-klieb żgħar
1
150
480
Activyl
Tick Plus soluzzjoni
_spot-on_
għal-klieb medji
2
300
960
Activyl
Tick Plus soluzzjoni
_spot-on_
għal-klieb kbar
4
600
1920
Activyl
Tick Plus soluzzjoni
_spot-on_
għal-klieb kbar ħafna
6
900
2880
Soluzzjoni ċara, mingħajr kulur li jkanġi fl-isfar jew fil-kannella
4.
INDIKAZZJONI(JIET)
Trattament ta’ infestazzjonijiet bil-briegħed (
_Ctenocephalides felis)_
; il-prodott għandu effett
insettiċidali persistenti sa’ 4 ġimgħat kontra
_Ctenocephalides felis. _
_ _
Il-prodott għandu effett akaraċidali sa’ 5 ġimgħat kontra
_Ixodes ricinus_
u sa 3 ġimgħat kontra
_Rhipicephalus sanguineus_
. Jekk qurdien minn dawn l-ispeċi jkunu preżenti meta l-prodott
jiġi
applikat, jista’ jkun li l-qu
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
Prodott mediċinali li m’għadux awtorizzat
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Activyl Tick Plus 75 mg + 240 mg soluzzjoni
_spot-on_
għal klieb żgħar ħafna
Activyl Tick Plus 150 mg + 480 mg soluzzjoni
_spot-on_
għal klieb żgħar
Activyl Tick Plus 300 mg + 960 mg soluzzjoni
_spot-on_
għal klieb medji
Activyl Tick Plus 600 mg + 1920 mg soluzzjoni
_spot-on_
għal klieb kbar
Activyl Tick Plus 900 mg + 2880 mg soluzzjoni
_spot-on_
għal klieb kbar ħafna
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
SUSTANZA ATTIVA:
Ml wieħed fiħ 150 mg indoxacarb u 480mg permethrin
Doża f’pipetta waħda tagħti:
DOŻA WAĦDA
(ML)
INDOXACARB
(MG)
PERMETHRIN
(MG)
Klieb żgħar ħafna (1.2 sa 5 kg)
0.5
75
240
Klieb żgħar (5.1 to 10 kg)
1
150
480
Klieb medji (10.1 sa 20 kg)
2
300
960
Klieb kbar (20.1 sa 40 kg)
4
600
1920
Klieb kbar ħafna (40.1 sa 60 kg)
6
900
2880
INGREDJENTI OĦRA:
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni
_spot-on _
Soluzzjoni ċara, mingħajr kulur li jkanġi fl-isfar jew fil-kannella
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Trattament ta’ infestazzjonijiet bil-briegħed (
_Ctenocephalides felis)_
; il-prodott għandu effett
insettiċidali persistenti sa’ 4 ġimgħat kontra
_Ctenocephalides felis. _
_ _
Il-prodott għandu effett akaraċidali sa’ 5 ġimgħat kontra
_Ixodes ricinus_
u sa 3 ġimgħat kontra
_Rhipicephalus sanguineus_
. Jekk qurdien minn dawn l-ispeċi jkunu preżenti meta l-prodott
jiġi
applikat, jista’ jkun li l-qurdien kollu ma jinqatilx fl-ewwel 48
siegħa imma jistgħu jinqatlu fi żmien
ġimgħa.
Briegħed fi stadji ta’ żvilupp li jkunu fl-ambjent immedjat
tal-kelb imutu hekk kif jiġu f’kuntatt ma’
klieb ittrattati.
Trattament wieħed jipprovdi attività repellenti (kontra l-ikel)
kontra sand flies (
_Phlebo
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-10-2022
Public Assessment Report Public Assessment Report Bulgarian 04-10-2022
Patient Information leaflet Patient Information leaflet Spanish 04-10-2022
Public Assessment Report Public Assessment Report Spanish 04-10-2022
Patient Information leaflet Patient Information leaflet Czech 04-10-2022
Public Assessment Report Public Assessment Report Czech 04-10-2022
Patient Information leaflet Patient Information leaflet Danish 04-10-2022
Public Assessment Report Public Assessment Report Danish 04-10-2022
Patient Information leaflet Patient Information leaflet German 04-10-2022
Public Assessment Report Public Assessment Report German 04-10-2022
Patient Information leaflet Patient Information leaflet Estonian 04-10-2022
Public Assessment Report Public Assessment Report Estonian 04-10-2022
Patient Information leaflet Patient Information leaflet Greek 04-10-2022
Public Assessment Report Public Assessment Report Greek 04-10-2022
Patient Information leaflet Patient Information leaflet English 04-10-2022
Public Assessment Report Public Assessment Report English 04-10-2022
Patient Information leaflet Patient Information leaflet French 04-10-2022
Public Assessment Report Public Assessment Report French 04-10-2022
Patient Information leaflet Patient Information leaflet Italian 04-10-2022
Public Assessment Report Public Assessment Report Italian 04-10-2022
Patient Information leaflet Patient Information leaflet Latvian 04-10-2022
Public Assessment Report Public Assessment Report Latvian 04-10-2022
Patient Information leaflet Patient Information leaflet Lithuanian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-10-2022
Public Assessment Report Public Assessment Report Lithuanian 04-10-2022
Patient Information leaflet Patient Information leaflet Hungarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-10-2022
Public Assessment Report Public Assessment Report Hungarian 04-10-2022
Patient Information leaflet Patient Information leaflet Dutch 04-10-2022
Public Assessment Report Public Assessment Report Dutch 04-10-2022
Patient Information leaflet Patient Information leaflet Polish 04-10-2022
Public Assessment Report Public Assessment Report Polish 04-10-2022
Patient Information leaflet Patient Information leaflet Portuguese 04-10-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-10-2022
Public Assessment Report Public Assessment Report Portuguese 04-10-2022
Patient Information leaflet Patient Information leaflet Romanian 04-10-2022
Public Assessment Report Public Assessment Report Romanian 04-10-2022
Patient Information leaflet Patient Information leaflet Slovak 04-10-2022
Public Assessment Report Public Assessment Report Slovak 04-10-2022
Patient Information leaflet Patient Information leaflet Slovenian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 04-10-2022
Public Assessment Report Public Assessment Report Slovenian 04-10-2022
Patient Information leaflet Patient Information leaflet Finnish 04-10-2022
Public Assessment Report Public Assessment Report Finnish 04-10-2022
Patient Information leaflet Patient Information leaflet Swedish 04-10-2022
Public Assessment Report Public Assessment Report Swedish 04-10-2022
Patient Information leaflet Patient Information leaflet Norwegian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-10-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-10-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-10-2022
Patient Information leaflet Patient Information leaflet Croatian 04-10-2022
Public Assessment Report Public Assessment Report Croatian 04-10-2022

Search alerts related to this product